[HTML][HTML] Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul, JC Horvat… - Atherosclerosis, 2022 - Elsevier
Background and aims Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul… - …, 2022 - researchnow.flinders.edu.au
Background and aims: Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial.
S Ren, PM Hansbro, W Srikusalanukul… - …, 2022 - opus.lib.uts.edu.au
BACKGROUND AND AIMS: Observational studies have demonstrated that the
pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of …
pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of …
[PDF][PDF] Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul… - …, 2022 - nova.newcastle.edu.au
Background and aims: Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul, JC Horvat… - 2022 - pubmed.ncbi.nlm.nih.gov
Background and aims Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
[PDF][PDF] Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro… - …, 2022 - researchnow-admin.flinders.edu.au
Background and aims: Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul… - …, 2022 - research.monash.edu
Background and aims: Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
S Ren, PM Hansbro, W Srikusalanukul… - …, 2022 - atherosclerosis-journal.com
Background and aims Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial.
S Ren, PM Hansbro, W Srikusalanukul, JC Horvat… - …, 2022 - europepmc.org
Methods A subgroup of participants at one centre (Canberra; n= 1,001) were evaluated at 1
month and 2 years post immunisation for changes in surrogate markers of atherosclerosis …
month and 2 years post immunisation for changes in surrogate markers of atherosclerosis …
Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: early results from a randomised controlled trial.
S Ren, PM Hansbro, W Srikusalanukul, JC Horvat… - 2022 - cabidigitallibrary.org
Background and aims: Observational studies have demonstrated that the pneumococcal
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …
polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This …